---
document_datetime: 2023-09-21 17:56:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/myozyme-epar-all-authorised-presentations_en.pdf
document_name: myozyme-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8684746
conversion_datetime: 2025-12-21 23:16:51.157207
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU number       | Invented name   | Strength   | Pharmaceutical Form                              | Route of administration   | Packaging    | Content   | Package size   |
|-----------------|-----------------|------------|--------------------------------------------------|---------------------------|--------------|-----------|----------------|
| EU/1/06/333/001 | Myozyme         | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 20 ml     | 1 vial         |
| EU/1/06/333/002 | Myozyme         | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 20 ml     | 10 vials       |
| EU/1/06/333/003 | Myozyme         | 50 mg      | Powder for concentrate for solution for infusion | Intravenous use           | Vial (glass) | 20 ml     | 25 vials       |